
machineMD
Radically improving the early diagnosis of brain disorders.
- B2B
- marketplace & ecommerce
- commission
- health
- health platform
- medical devices
- artificial intelligence
- deep tech
- virtual reality
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor | €0.0 | round | |
N/A | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor | €0.0 | round | |
investor investor | €0.0 | round | |
investor | €0.0 | round | |
* | N/A | Early VC | |
Total Funding | 000k |
USD | 2022 | 2023 |
---|---|---|
Revenues | 0000 | 0000 |
% growth | - | 244 % |
EBITDA | 0000 | 0000 |
Profit | 0000 | 0000 |
EV | 0000 | 0000 |
EV / revenue | 00.0x | 00.0x |
EV / EBITDA | 00.0x | 00.0x |
R&D budget | 0000 | 0000 |
Source: Dealroom estimates
Related Content
MachineMD is a medical device startup that specializes in neuro-ophthalmology, a field that focuses on diagnosing and monitoring neurological disorders through the analysis of eye and pupil movements. The company was founded at the University Hospital of Bern, Switzerland, with a mission to standardize, automate, and quantify medical examinations, thereby improving the quality and efficiency of healthcare.
MachineMD's primary target market includes secondary and primary care providers who may not have access to highly trained specialists. The company aims to bring the diagnostic quality of a tertiary care specialist to these healthcare providers. MachineMD's business model is centered around the development and sale of their proprietary medical devices and technology.
The company's main product, Neos, offers new examination methods that expand the diagnostic capabilities of healthcare providers. It is designed to be easy to use, making it appealing not just to specialists but also to general practitioners. The potential of Neos has been demonstrated in a study conducted by researchers at the University Hospital of Bern, which presented an accurate, fast, and easy-to-use method to measure a Relative Afferent Pupillary Defect (RAPD), a condition often associated with optic nerve damage.
MachineMD has garnered support and collaboration from various companies and institutions in the medtech and innovation sectors. It has also made significant strides in the DayOne 4.0 Health Accelerator program, having been selected for the final phase.
In terms of revenue, MachineMD likely generates income through the sale of its Neos device and possibly through partnerships and collaborations in the medtech and innovation fields.
Keywords: Medical Device, Neuro-Ophthalmology, Healthcare Efficiency, Automated Medical Examinations, Primary Care, Secondary Care, Tertiary Care, Medtech, Innovation, Health Accelerator.